Sirolimus (Rapamycin) for the Targeted Treatment of the Fibrotic Sequelae of Graves’ Orbitopathy

Eye - United Kingdom
doi 10.1038/s41433-019-0340-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Amsterdam Declaration on Graves' Orbitopathy

2017English

The Amsterdam Declaration on Graves' Orbitopathy

Thyroid
MedicineEndocrinologyMetabolismDiabetes
2010English

Life-Threatening Complications of High Doses of Intravenous Methylprednisolone for Treatment of Graves’ Orbitopathy

Thyroid Research
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2019English

Modeling Graves’ Orbitopathy in Experimental Graves’ Disease

Hormone and Metabolic Research
BiochemistryEndocrinologyClinical BiochemistryMedicineMetabolismDiabetes
2015English

Clinical Assessment of Patients With Graves' Orbitopathy

Medicinski glasnik Specijalna bolnica za bolesti stitaste zlezde i bolesti metabolizma Zlatibor
2011English

Systemic Toxicity Following Administration of Sirolimus (Formerly Rapamycin) for Psoriasis

Archives of Dermatology
1999English

THERAPY OF ENDOCRINE DISEASE: Endocrine Dilemma: Management of Graves’ Orbitopathy

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2016English

Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis

Ophthalmology
Ophthalmology
2018English

Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients

Frontiers in Endocrinology
EndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy